title: Post-marketing surveillance of lisinopril in general practice in the UK.
abstract: A total of 4676 patients and 1759 patients were treated with lisinopril and nifedipine respectively in a post-marketing surveillance study conducted in general practice in the UK. Patients were followed up for 12 months. Most of the lisinopril patients had hypertension, but a small number (180) had heart failure. Most of the nifedipine patients had uncomplicated hypertension, but some (22.57%) had other cardiovascular disease with or without hypertension. Lisinopril and nifedipine were equally effective in reducing blood pressure. During the study, 1.5% of hypertensive patients assigned to lisinopril died compared with 1.8% of patients assigned to nifedipine, and 15.1% of lisinopril patients compared with 19.7% of patients in the nifedipine group withdrew because of adverse events. Cough, malaise and fatigue, nausea and vomiting were more frequent causes of withdrawal from lisinopril than nifedipine. Conversely, headaches, pallor and flushing, oedema and palpitations caused more frequent withdrawals from nifedipine. Anaemia was more often encountered on nifedipine treatment than on lisinopril. In hypertensive patients, the frequency of first-dose hypotension was similar on both treatments. Serious events occurred in 0.8% and 0.5% of patients given lisinopril and nifedipine respectively. Lisinopril was well tolerated by heart failure patients: 16 patients (8.88%) died and an incidence of 4.44% of serious adverse events was reported, a pattern to be anticipated in such patients; dizziness, giddiness, dyspnoea, cough, nausea and vomiting were the most frequent causes of withdrawal; the incidence of first-dose hypotension was low (2.22%).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Medical Affairs Department, ZENECA Pharmaceuticals, Alderley Park, Macclesfield, Cheshire.
authors.forename: J M
authors.initials: JM
authors.lastname: Fallowfield
authors.forename: J
authors.initials: J
authors.lastname: Blenkinsopp
authors.forename: A
authors.initials: A
authors.lastname: Raza
authors.forename: A G
authors.initials: AG
authors.lastname: Fowkes
authors.forename: T J
authors.initials: TJ
authors.lastname: Higgins
authors.forename: K M
authors.initials: KM
authors.lastname: Bridgman
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005194:Family Practice; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000401:mortality; D017706:Lisinopril / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000188:drug therapy; D009543:Nifedipine / Q000627:therapeutic use; D011358:Product Surveillance, Postmarketing; D006113:United Kingdom
chemical_list: D017706:Lisinopril; D009543:Nifedipine